Bright Minds Biosciences Announces Phase 2 Clinical Trial To Evaluate BMB-101 In Drug-Resistant Epilepsy Disorders With High Unmet Needs; Financial Runway Extends Into 2026, Webcast Scheduled For September 25th
Author: Benzinga Newsdesk | September 12, 2024 08:06am